Knights of Columbus Asset Advisors LLC Boosts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Knights of Columbus Asset Advisors LLC lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 125.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,804 shares of the medical equipment provider’s stock after purchasing an additional 26,059 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Lantheus were worth $2,902,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Tucker Asset Management LLC boosted its holdings in shares of Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 160 shares during the period. First Horizon Advisors Inc. lifted its holdings in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 225 shares during the period. Covestor Ltd lifted its holdings in Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 203 shares during the period. Finally, Coppell Advisory Solutions LLC purchased a new stake in Lantheus in the second quarter worth about $46,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $63.81 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $100.85. The company has a 50 day simple moving average of $60.81 and a two-hundred day simple moving average of $62.88. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of 13.75 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Insider Activity at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. B. Riley raised their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday. Truist Financial restated a “buy” rating and issued a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. JMP Securities restated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Finally, StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.71.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.